Robert Dillard

Robert Dillard is a contributing writer for GU Oncology Now and its parent company, Mashup Media, LLC. As a medical writer and editor, Mr. Dillard is experienced at producing high-quality clinical articles, blog articles, news releases, white papers, and educational and promotional content. Mr. Dillard has been writing in the health care space for more than 7 years and previously served as a public relations specialist. He received his BA in public relations from Rowan University.

Articles by Robert Dillard

Robert DillardRLT-PSMA | December 21, 2022
A study sought to assess organoids and short-term ex vivo cultures of prostate cancer.
Read More
Robert DillardRLT-PSMA | December 21, 2022
Researchers developed the first validated risk model for discerning personalized prostate cancer risks.
Robert DillardRLT-PSMA | December 21, 2022
A risk score can predict prostate cancer in men of African ancestry.
Robert DillardRLT-PSMA | December 21, 2022
A greater family history of prostate cancer is associated with a lower risk of mortality.
Robert DillardIKCS 2022 | December 18, 2022
A study evaluated how accurately prospectively collected renal mass biopsy can identify DNA mutations in nephrectomy.
Robert DillardIKCS 2022 | December 18, 2022
Gut bacteria play a role in the development of sarcopenia in metastatic renal cell carcinoma.
Robert DillardIKCS 2022 | December 18, 2022
Following AUA guidelines may increase survival in kidney cancer.
Robert DillardIKCS 2022 | December 18, 2022
An algorithm for assessing solid renal masses called the kidney MR score proved successful in differentiating lesions.
Robert DillardIKCS 2022 | December 14, 2022
Active surveillance appears effective in renal transplant candidates and immunocompromised patients with small renal mass.
Robert DillardIKCS 2022 | December 14, 2022
Immune-oncology agents and tyrosine kinase inhibitors are increasingly being used in treating metastatic kidney cancer.
Robert DillardIKCS 2022 | December 14, 2022
Patients presenting with nasal or paranasal sinuses tumors should be checked for metastatic kidney cancer.
Robert DillardIKCS 2022 | December 14, 2022
Patients with kidney cancer who exercise and stay physically active have better physical and mental health.
Robert DillardIKCS 2022 | December 9, 2022
Artificial intelligence models can accurately predict cardiotoxicity risk in patients with renal cell carcinoma.
Robert DillardIKCS 2022 | December 9, 2022
Patients who undergo treatment for renal cell carcinoma (RCC) have a 10-times greater risk of end-stage renal disease (ESRD).
Robert DillardIKCS 2022 | December 9, 2022
Cabozantinib and avelumab appears safe and effective in patients with metastatic clear cell renal carcinoma.
Robert DillardIKCS 2022 | December 9, 2022
Patients with advanced renal cell carcinoma demonstrate better responses on nivolumab plus cabozantinib.
Robert DillardRLT-PSMA | November 18, 2022
A polygenic hazard score (PHS290) is able to stratify US veterans of diverse ancestry for lifetime risk of prostate cancer.
Robert DillardRLT-PSMA | November 18, 2022
A study assessed the link between benign prostatic hyperplasia (BPH) and prostate cancer (PCa).
Robert DillardRLT-PSMA | November 18, 2022
A corrected genetic risk score (GRS) based on non-European racial/ethnic populations is more appropriate for genetic testing.
Robert DillardRLT-PSMA | November 18, 2022
Genetic testing rates are low for prostate cancer.